Related Experiment Video
Updated: Jun 8, 2026

Working with Human Tissues for Translational Cancer Research
Published on: November 26, 2015
An open letter to institutional review boards considering Northfield Laboratories' PolyHeme® trial
Ken Kipnis1, Nancy M P King, Robert M Nelson
1University of Hawaii at Manoa, USA.
Abstract:
At the time of this writing, a widely publicized, waived-consent trial is underway. Sponsored by Northfield Laboratories, Inc. (Evanston, IL) the trial is intended to evaluate the emergency use of PolyHeme®, an oxygen-carrying resuscitative fluid that might prevent deaths from uncontrolled bleeding. The protocol allows patients in hemorrhagic shock to be randomized between PolyHeme® and saline in the field and, still without consent, randomized between PolyHeme® and blood after arrival at an emergency department. The Federal regulations that govern the waiver of consent restrict its applicability to circumstances where proven, satisfactory treatments are unavailable. Blood-the standard treatment for hemorrhagic shock-is not available in ambulances but is available in hospitals. The authors argue that the in-hospital stage of the study fails to meet ethical and regulatory standards.
More Related Videos
04:53A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
08:19Protocol for the Evaluation of MRI Artifacts Caused by Metal Implants to Assess the Suitability of Implants and the Vulnerability of Pulse Sequences
Published on: May 17, 2018
Related Concept Videos
Bioequivalence studies: Biowaivers
Clinical Trials: Overview
Clinical Trials
There are four phases in a clinical trial. A phase one...
Drug Regulation
Ethics in Research